Amarin reported $-16755000 in Operating Profit for its fiscal quarter ending in March of 2025.


Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
Amarin USD -16755000 35.77M Mar/2025
AstraZeneca USD 3.51B 166M Jun/2025
DBV Technologies USD -41110000 14.49M Jun/2025
GlaxoSmithKline GBP 2.02B 193M Jun/2025
Halozyme Therapeutics USD 202.44M 60.91M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD 4.86B 201M Jun/2025